Madrigal Pharmaceuticals, Inc. (MDGL)
571.29
-0.04
(-0.01%)
USD |
NASDAQ |
Dec 12, 16:00
580.49
+9.20
(+1.61%)
After-Hours: 20:00
Madrigal Pharmaceuticals Research and Development Expense (Quarterly): 173.65M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen, Inc. | 1.90B |
| Alnylam Pharmaceuticals, Inc. | 358.81M |
| Amicus Therapeutics, Inc. | 23.42M |
| Insmed, Inc. | 186.42M |
| Ionis Pharmaceuticals, Inc. | 217.13M |